Dysregulation of IL-6/MCP-1/STAT3 Axis: A Promising Therapeutic Postinfarction Inflammation Strategy?
- PMID: 38984047
- PMCID: PMC11228117
- DOI: 10.1016/j.jacbts.2024.03.006
Dysregulation of IL-6/MCP-1/STAT3 Axis: A Promising Therapeutic Postinfarction Inflammation Strategy?
Keywords: IL-6; MCP-1; STAT3; inflammation; macrophages; myocardial infarction.
Conflict of interest statement
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Comment on
- doi: 10.1016/j.jacbts.2024.01.019
References
-
- Mitsis A., Kadoglou N.P.E., Lambadiari V., et al. Prognostic role of inflammatory cytokines and novel adipokines in acute myocardial infarction: an updated and comprehensive review. Cytokine. 2022;153 - PubMed
-
- Broch K., Anstensrud A.K., Woxholt S., et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77:1845–1855. - PubMed
-
- de Lemos J.A., Morrow D.A., Sabatine M.S., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690–695. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous